On CNBC’s "Mad Money Lightning Round," Jim Cramer said he really likes Qualtrics International Inc XM as a "long-term growth play."
Analysts strongly agree, giving XM an Outperform consensus rating, according to Benzinga's analyst ratings data.
When asked about Clearfield Inc CLFD, he said, "There’s an analyst that cut numbers and the stock fell apart. That was ridiculous."
Don’t forget to check out our premarket coverage here
Cramer said CRISPR Therapeutics AG CRSP is "one of those crazy science stocks that in this market will work perfectly."
Price Action: Shares of Qualtrics were up 5.74% at $16.66, Clearfield was down 1.2% to $70.60, while CRISPR Therapeutics shares were 2% higher at $52.00 on Wednesday morning.
Now Read This: Over $5M Bet On Uber Technologies? Check Out These 4 Stocks Insiders Are Buying
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.